Regulated information
Waregem (Belgium)/Rotterdam (The Netherlands)1, 10 May 2016
Fagron shareholders approve all proposed resolutions during annual shareholders meeting
Jan Peeters steps down as CFO
Fagron announces that its annual general meeting of shareholders, held on 9 May 2016, has adopted all proposed resolutions. The meeting approved the 2015 financial statements and discharged the directors and the statutory auditor who were active during the financial year 2015. In addition, the meeting decided to re-appoint PricewaterhouseCoopers as statutory auditor for three years.
Changes in the Board of Directors and the Executive Committee
Jan Peeters announces that he has decided to resign and is stepping down as director and CFO of Fagron with immediate effect. The Board of Directors has unanimously decided to appoint Mrs. Karin de Jong, employed by Fagron since May 2008, as CFO. Mrs. De Jong is currently Group Controller and member of the Executive Committee of Fagron. Jan Peeters will remain available to hand over to his successor and will stay on as an advisor to the company until the end of this year.
Robert Peek, Chairman of the Board of Directors: “We are grateful for the contribution of Mr. Peeters to Fagron, especially for his efforts in the recent period in which we realized the new financing of the company. Now that this is concluded, Jan has decided to step down and to concentrate on other things. We wish him all the best for the future.”
In addition, the Board of Directors has appointed Mrs. Rita Hoke as member of the Executive Committee and as President of Fagron North America. In this position Mrs. Hoke will directly report to Hans Stols, CEO of Fagron. As announced on 5 February 2016, Hans Stols temporarily acted as President of Fagron North America after Jacob Jackson left.
Mrs. Hoke is a pharmacist and started her career at Baxter Healthcare, a leading American healthcare company, where she worked in roles of increasing responsibility across multiple functions. From 2004 until 2011, she was responsible for the hospital division in the United States for Grifols, a Spanish multinational active in healthcare and bioscience. Since 2011, she has been active as an advisor for multinationals that are or want to become active in the compounding business in the United States.
In the event of differences between the English translation and the Dutch original of the press release, the latter prevails
1 This press release was sent out by Fagron NV and Fagron BV.
For more information:
Constantijn van Rietschoten
Chief Marketing Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Profile Fagron
Fagron is a scientific pharmaceutical R&D business focused on optimising and innovating personalised pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
Please open the link below for the press release: